Jason Ehrlich Sells 2,282 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) Stock

Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) insider Jason Ehrlich sold 2,282 shares of Kodiak Sciences stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $7.02, for a total transaction of $16,019.64. Following the completion of the transaction, the insider now directly owns 56,920 shares in the company, valued at approximately $399,578.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jason Ehrlich also recently made the following trade(s):

• On Wednesday, June 15th, Jason Ehrlich sold 1,205 shares of Kodiak Sciences stock. The stock was sold at an average price of $7.21, for a total transaction of $8,688.05.

KOD opened at $7.91 on Friday. Kodiak Sciences Inc. has a twelve month low of $4.90 and a twelve month high of $26.39. The company has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $34.41.

Kodiak Sciences (NASDAQ:KOD – Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($1.83) EPS for the quarter, missing analysts’ consensus estimates of ($1.51) by ($0.32). During the same period in the previous year, the company earned ($0.98) EPS. As a group, analysts anticipate that Kodiak Sciences Inc. will post -7.06 EPS for the current fiscal year.

A number of analysts have recently commented on the stock. Chardan Capital reissued a “buy” rating on shares of Kodiak Sciences in a research report on Monday, April 11th. Roth Capital lowered their target price on shares of Kodiak Sciences from $149.00 to $75.00 in a report on Monday, February 28th. Citigroup lowered their target price on shares of Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 24th. JPMorgan Chase & Co. downgraded shares of Kodiak Sciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $90.00 to $21.00 in a report on Thursday, February 24th. Finally, Truist Financial decreased their price objective on shares of Kodiak Sciences from $147.00 to $35.00 in a report on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $45.33.

Several hedge funds have recently bought and sold shares of KOD. Lindbrook Capital LLC raised its holdings in Kodiak Sciences by 2,160.0% in the 4th quarter. Lindbrook Capital LLC now owns 565 shares of the company’s stock valued at $48,000 after buying an additional 540 shares during the last quarter. Marshall Wace North America L.P. bought a new position in Kodiak Sciences in the 1st quarter valued at approximately $73,000. Exane Derivatives raised its holdings in Kodiak Sciences by 8,472.7% in the 4th quarter. Exane Derivatives now owns 943 shares of the company’s stock valued at $80,000 after buying an additional 932 shares during the last quarter. Tiedemann Advisors LLC bought a new position in Kodiak Sciences in the 1st quarter valued at approximately $92,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Kodiak Sciences in the 1st quarter valued at approximately $101,000. 69.80% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Further Reading